Company Profile
Samsung Biologics
— A giant contract manufacturer of antibodies expanding into ADCs and peptides
Samsung Biologics has a factory in Songdo, Incheon, KoreaBiopharmaceu s (CDMO)Comment Most of the sales were kept from the pharmaceutical companyPreparation of antibody medicine with large-scale cultivation equipmentBorn from. It is 3 points to be noted in the viewpoint of drug discovery and DDS. First, combine the drug into the antibodyADC factoryThe injection filling line is under construction. The second is the biosimilar business (Samsung Bioepis).In November 2025, the company split into Samsung Epis HoldingsWe have become a contracted company that does not have our own medicine. The third is in July 2026Acquisition of PolyPeptideAs of September 2026 This paper is not deep into cell culture and plant capacity itself,ADCs, preparations, and peptidesFilter by
- Samsung Biologics Understanding in 30 Seconds and Standing Position in Drugs and DDS
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- Company size
- Drug discovery and DDS resources
- Past Initiatives
- Future plans
- What is DDS?
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary/Source/Ins ment and Source Response Table
1. Standing position with Samsung Biologics in 30 seconds and DDS
Co., Ltd.Korean Established in 2011
KRX: 207940Securities Market (KOSPI)
（CDMO）Separation of our pharmaceutical business in November 2025
Businesses related to drug discovery and DDS are largePharmaceutical Company / Biotech / Contract Development Manufacturing (Research)3 types. Samsung BiologicsContract development manufacturingHome FactsHome Previously, Samsung Bioepis developed and marketed biosimilar (patented antibodies), The company split on November 1, 2025.Samsung Epis HoldingsI moved to the bottom of the umbrella. DART's business report is the purpose of splitting "with the biosimilar business"Conclude the conflict of interestand strengthen a separate decision-making system. Research and DevelopmentNo development completedI wrote. This companyWe do not have our own medicine, and we dedicate ourselves to making other drugsI made a stand clear in the form of an organization.
2. Logo and company name
Samsung Biologics。 In this article, we do not reproduce the generated image,
Logo displayed at the top of the official website (SVG)Home img/samsung_biologics_logo.svg Contact Us
Note: In Japanese, it is written as "Samsung Biologis". Samsung BioepisHomeSamsung Epis Holdingssince November 2025Not a subsidiary of Samsung BiologicsHome There are many similar names, so this article distinguishes three companies. In addition, a direct subsidiary established by Samsung Biologics in Switzerland Samsung Peptide AG Comment The company will appear in the business description of the cell culture technology of this series.What I wrote separately from the viewpoint of drug discovery and DDSComment
Official Site:https://samsungbiologics.com/3. Where is this company in the world of drug discovery and DDS?
TypeCDMOin the center modalitiesAntibodyComment The majority of sales in 2025 are contracted manufacturing of antibody drugs (CMO), which includes development contracts (CDO) until initial clinical practice and research contracts by Olgagrad, which began in June 2025. FactsHome DDSADC to “carry” antibody、Injection preparation (high concentration preparation, prefilled syringe)and propose acquisitionsPeptidesThis series of technical commentary "CDMO", "antibody medicine and ADC" and "peptide medicine and GLP-1" can be read easily.
4. Company Scope
The split biosimilar business is divided into non-co ous business, and the following numbers areContract development businessHome Facts。
| Indicators (Million won) | FY2024 | FY2025 | Year 2026 |
|---|---|---|---|
| Sales (Consolidated) | 34,971 | 45,570 | 25,780 |
| Operating income (consolidated) | 13,214 | 20,681 | 11,670 |
| R&D expenses (consolidated) | 1,416 | 1,674 | Not specified in the release |
| R&D expenses vs. sales ratio | 4.1% | 3.7% | ― |
| 5,000 people | December 31, 2025 | |
| Research and Development | 609 people | 109 Doctors, including 266 Masters |
| Production capacity (Total capacity of culture tank) | 845,000L | 785,000L in Matsushima and 60,000L in Rockville, USA |
| Sales by Region | European 52.0%, USA 38.0% | 2025. 8.2% in Japan |
| Total Order | US$216 billion | As of June 30, 2019 |
| 2026 Outlook | Consolidated sales +15 to 20% | In July 2026, it was announced that it is in the process of achieving the maximum forecast |
The above numbersCompany OverviewThe sales of ADC and formulations are not disclosed separately Undetermined / FutureHome 2025 sales95.6% of antibody drugsADC is stillStart-up BusinessComment In addition, the business report includes the number of biopharmaceu、 market ($5,387 billion in 2025 and 10.6% in 2030). Because it cannot be determined based on the estimate of the investigative company specified by the source,This article does not work。
5. Drug discovery and DDS resources
| Resource Types | ||
|---|---|---|
| People (R&D) | 609 people, 297 manufacturing technologies (MSAT), 194 CDO development centers, and 118 bio research institutes. The number of people in charge of ADC is not disclosed | Facts |
| People (Face of Research System) | The Director of Bio Research Institute was the Director of Biocenter of RigaChem Biosciences. AI Lab | Facts |
| Gold (R&D expenses) | 1,674 billion won (2025, consolidated). Work expenses 935 billion won | Facts |
| Gold (ADC Equipment) | ADC factory completed GMP preparation in 2025.Contract for construction of ADC injection (DP) plantSigned with a construction company in Japan on November 14, 2025, with a contract of 524 billion won (value-added tax) | Facts |
| Gold (Future investment) | Plan to pitch approximately 7 trillion KRW by 2034 to the 3rd Bio Campus (2,486 billion KRW). The acquisition of PolyPeptide with approximately 2.71 trillion KRW of shareholder allotment in August 2026. | Facts |
| PolyPeptide Group(Contracted by Peptide Original Drugs) is available at 44.31CHF per share and total price of about 14.6 billion CHF. Rockville, USA (GSK, US$3.53 billion, acquired in March 2026) | Facts | |
| External investment | Samsung Life Science Fund Araris(2023),Aimed Bio(2023) Protein Engineering for ADC BrickBio(2024), ADC platform company in China Phrontline BiopharmaInvested in 2025. In June 2026, invested in 20 billion won for the third fund. | Facts |
| Introduction of technology | DART's Business Report Forms License-in-Lic、-Out Technical Partnership AgreementNoneContact Us | Facts |
| Public Funds | Research and Development CostGovernment subsidies are not applicableContact Us | Facts |
| Collaboration with universities and research institutions | Strategic alliance with CEPI in 2026. No joint research with universities on ADC and peptides | Not confirmed |
The company's bioconjugation business page has a dedicated ADC factory.Production and operation of other biologicsHome To treat high pharmacological activity original medicine (HPAPI)Occupational exposure limit (OEL) less than 1 ng/m3It is written that it has an enclosed facility designed to achieve. Reaction equipmentBoth single-use and stainless steelSupports up to 500L series FactsHome 1 ng/m3 is 1 billion grams per cubic meter. In addition to the design of iso、 devices and negative pressure to protect workers,How to safely dispose of disposable bags, tubes and filters after high-toxic liquidsis part of the design of the process. The combination of single-use and stainless steel can be read with the speed of product ( ) and the producibility (stainless) on a large scale. Undetermined / Future。
6. Past Initiatives
| Time | Home | |
|---|---|---|
| Year 2011 | Established Samsung Biologics | Depart from antibody contract manufacturing |
| May 2021 | Moderna and COVID-19 mRNA vac。 formulation (DP) production contract. In December of the same year, the company acquired approval of the Korea Food and Drug Safety Office (MFDS) for its production (in the history). | Result of filling injections and contracting of mRNA |
| 2022 year | Production equipment of mRNA is operated. Completed commercial testing operation of mRNA vac。 in August. Samsung Bioepis became 100% subsidiary in April | First expansion to new modalities |
| April 2023 | Life Science FundAraris with ADC technologyInvestment | Interest in ADC starts in the form of investment |
| February 2024 | LigaChem Biosciences and ADCHome Expanded collaboration in January 2025 | First Publication of ADC Contract |
| October 2024 | High concentration formulation platform S-HiCon | Enhancing contract development of injection formulation |
| February 2025 | ADC dedicated factory completed CGMP preparation(Financial Report) | ADC join process |
| June 2025 | Started “Samsung oids” for drug discovery screening | Material with customers from the stage of searching for candidate substances (CRO) |
| November 2025 | Company Split (November 1)Home Launched Samsung Epis Holdings to develop and commercialize biosimilars. Contract for construction of ADC injection plant on 14th (524 billion won) | Contact Us Prepare to connect ADC's "combination to filling" |
| November 2025 | Life Science Fund invests in Phrontline Biopharma, a Chinese ADC platform company. Bio the 3rd bio campus | Continued investment in ADC technology |
| Q1 2026 | First commercial engineering run at ADC dedicated factoryComplete. Strategic Partnership with CEPI and Open Innovation withli Lilly | Demonstration for ADC commercial production |
| March 2026 | Completed acquisition of Rockville factory (60,000L) | First manufacturing base in the United States |
| July 20, 2026 | PolyPeptide Group Announces Full Cash Release(1 share 44.31CHF, total: 14.6 billion CHF) | To peptide outside of antibody and ADC |
| August 28, 2026 | Announcement of shareholder allocation of approximately 3 trillion KRW. The 6th to 8th factory is running separately, and the concept to make the total capacity 1,385,000L in 2032 is announced. | Acquisition and expansion of funds |
| August 31, 2026 | Samsung Peptide AGAnnouncement of Public Buying StatementHome September 15 - October 12 | As of September 26, 2026 |
7. Future plans
Build Mother LinePre-packing the drug into the syringe
Schedule of November 30, 2026November 9-10
Business Report 2025Expansion of ADC production equipmentWe are writing to strengthen the production base of small and medium to meet the growing demand for clinical stage production. FactsHome ADC and small lot for clinical useSmall volume but difficult to processYou can see that you are trying to increase by consciousness.
Both of the following are not listed in Business Report and Official Release Undetermined / Future。
ADC dedicated factoryNumber of contracts, customer name, sales/ADC Injection Line and Prefilled SyringeProduction capacity/ LigaChem BiosciencesPrices and Items/Collaborate withli LillySpecific content and amount/ Acquisition of PolyPeptideIntegrated Planning and Additional InvestmentShopApplication statusHome PolyPeptide buys during the purchase period as of September 26, 2026.Not confirmed。
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| From a company with only antibody"One company with multiple modalities"Contact Us | The release of PolyPeptide’s acquisition is “to peptide drugs beyond antibody and ADC” and “CDMO of polymodality” | Facts |
| ADCAntibody -> Binding -> FillingAim for consistent contract | Completion of preparation for ADC dedicated plant, construction contract for ADC injection plant, and project page | |
| In peptidesDemand for GLP-1 for obesity and diabetesFor the biggest reason | The release raises global demand for obesity treatment, and “obesity and diabetes including GLP-1” | Facts |
| The acquisition of peptideExpand your location to the United States, Europe and IndiaGreat meaning | The CEO’s comment is “the geographical approach in the United States, Europe, and India,” and PolyPeptide’s six factories are located in Europe, the United States and India. | |
| ADC TechnologyUse the technology of the investor and the customer, not in-house | License-in-out is not applicable in business report. ADC technology is owned by Life Science Fund (Araris, Aimed Bio, BrickBio, etc.) | |
| SplitAvoid conflict of interest with customersWe made it easy to accept large pharmaceuticals. | Business report explains the purpose of splitting "resolve concern of conflict of interest with the biosimilar business" |
For a contracted company, the company's group develops biosimilars from a customer's pharmaceutical company“We will leave the manufacturing to the person who may make a subsequent product of our drug.”The purpose of the business report is to “resolve concerns of conflicts of interest” FactsHome The next one that the company chose after eight monthspeptides that do not have their own drugsthe acquisition. The two articles are:One policy of "inc、ing modalities that can be used as a trusted company without drugs"Read the first half and second half Undetermined / FutureHome Samsung Epis Holdings introduces its subsidiary (Episnex Lab), which develops peptide-related elemental technology platforms. Within the Samsung GroupBiologics for peptides is the Epis and peptides.It looks like it is becoming a role sharing Undetermined / FutureHome However, we cannot confirm the primary material which the company has officially explained this share.
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
| Contact | ||
|---|---|---|
| ADC Contract | We have contracted the process of preparation of antibody, preparation of payload, reduction, binding, non-filtration, chromatography refining, preparation and filling of chemical compounds. Analysis of drug antibody ratio (antibody), residual solvents and free drugs | GMP preparation completed (2025) Commercial scale test operation for the first quarter of 2026 |
| ADC preparation | ADC injection (DP) line is under construction | Planned to be built by 2027 |
| Production of antibodies | From large culture of original medicine (DS) to preparation. Double-specific antibodies and fusion proteins | Main business Total Capacity845,000L |
| Contract development | High concentration preparation platform S-HiCon, prefilled syringe motherline (plan) | S-HiCon announced in October 2024 |
| mRNA | Contract of mRNA original medicine and preparation | Production equipment started in 2022 |
| Contact Us | Patient-derived tumor models | June 2025 |
| Peptides | The acquisition of PolyPeptide has been completed and the peptide original drug is added in six GMP factories in Europe, the US and India. | Close(Opening) |
Antibody is a protein that can be made into cells.Cultivation tank, medium, purified resin, single use bagComment peptides are oftenMake in. According to PolyPeptide, the company has a history of over 70 years of original medicine manufacturing and a history of over 1,000 treatment peptides. Modularization and AutomationA company that has grown to the axis FactsHome Peptide connects amino acids one by one on resinSolid Phase Synis common.Synthetic resins, protected amino acids, large amounts of organic solvents, reversal chromatography fillersdepends on cost and environmental impact. This is almost unheard of the materials that Samsung Biologics has handled, If the acquisition is established, the company's suppliers and the subject of quality control will change greatly Undetermined / FutureHome The primary materials used by PolyPeptide, including the laws and solvents, are not specified in the primary material of Samsung Biologics, and the part of solid phase is a general explanation of this article.
11. Risks that this company has
| Risks | ||
|---|---|---|
| The possibility that the acquisition is not established | PolyPeptide's public purchase conditions are 662⁄3% or higher and regulatory approval. The maximum shareholder (approx. 55.65%) is committed to the application, but the results do not appear as of September 26, 2026. | Undetermined / Future |
| Di by capital increase | Issued a new stock of approximately 270,000 shares. The amount is equivalent to 4.90% of the market capital. | Facts |
| Focus on Sales | US (38.0。 with European (52.0。) Easy to understand changes in policy and commerce in Europe | Facts |
| Contact | A government litigation is followed by accounting for investments in Samsung Bioepis, seeking to revoke the disposal of securities futures committees. The company says that the results cannot be predicted. | Facts |
| Launch of ADC business | ADC has not yet published commercial production results. There are many predecessor companies in ADC contracts, but how many customers can earn | |
| Integration of different manufacturing technologies | A culture-centric company will take advantage of the peptide business, which is chemical-centric, and may take time to integrate quality systems and human resources. |
12. Glossary
- CDMO
- CDO and CMO In addition to the above contract (CRO), it is called CRDMO.
- ADC
- Antibody drug complex. A drug that connects strong drugs with a linker to antibodies that bind to the mark of cancer cells.
- DAR
- Drug-to-Antibody Ratio Number of drugs combined per of antibodies. Important indicators to determine the quality of ADC.
- OEL
- Job exposure limits. The upper limit of the concentration in the air that the worker does not get healthy even if it is sucked.
- Prefilled Syringe
- Preparation of chemical liquid in advance in the syringe. Patients and medical personnel can be injected as they are.
- Biosimilar
- A subsequent product approved as having the same quality, effectiveness and safety as a patented biopharmaceu .
- Peptides
- The active ingredient of the drug with several to dozens of amino acids. GLP-1 receptor agonists, etc.
- Public Buying
- Procedures to collect shares of listed companies outside the market, showing prices and periods.
Concept diagram of AI generation13. Source
- Samsung Biologics Submitted to the Financial Director's DART for the Fiscal Year Ending December 2025. 20d on May 15, 2026, Korean). Business overview, purpose of division, regional composition of sales, construction contract of ADC factory and ADC injection factory, planning of prefilled syringe, licensing and technical cooperation, organization and personnel of R&D, R&D expenses, whether there is government subsidy, market scale. https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515001658
- Samsung Biologics Business Report 2025 President’s Message (2026 Policy, Expansion of ADC Equipment, 3rd Biocampus Approx. 7 trillion won), History (history, Araris, RigaChem, Split, Phrontline, etc.), Number of employees, consolidated profits, split accounting, administrative litigation. https://samsungbiologics.com/common/fileDownload.do?_fdFileName_=cd21696118cd4a7daa6973c02d40f795.pdf&_colunmName_=attCnt0&_downloadIdx_=391&_fdFileOriName_=%5BSamsung%20Biologics%5D%202025%20Business%20Report.pdf&_fdSubPath_=investors
- Samsung Biologics 2025 Q4 Earnings Release(January 21, 2026). Consolidated sales forecast for 2026 (+15 - 20%), completion of division. https://samsungbiologics.com/common/fileDownload.do?_fdFileName_=61a7b9d576694f6c8a10151dfb7067f8.pdf&_colunmName_=attCnt0&_downloadIdx_=382&_fdFileOriName_=%5BSamsung-Biologics%5D-2025-Q4-Earnings-Release.pdf&_fdSubPath_=investors
- Samsung Biologics Press Release “Samsung Biologics reports first quarter 2026 financial results” (April 22, 2026). In collaboration with engineering Lilly, the first commercial-scale engineering run in the ADC dedicated plant, the acquisition amount of Rockville, and the CEPI. https://samsungbiologics.com/media/company-news/samsung-biologics-reports-first-quarter-2026-financial-results
- Samsung Biologics Samsung Biologics Reports Second Quarter 2026 Financial Results Achieved a maximum of $222 billion in sales and operating profits for the first half of 2026, Life Science Fund (co-investors and operators, Fund No.3) and forecasts. https://samsungbiologics.com/media/company-news/samsung-biologics-reports-second-quarter-2026-financial-results
- Samsung Biologics Press Release “Samsung Biologics Announces All-Cash Offer to Poly PolyPeptide,amelerating multi-modality strategy and global network across U.S., Europe, and India” (July 20, 2026). Comments from PolyPeptide's results and bases, CEO's comments, including purchase price, total amount, maximum shareholder commitment, conditions, peptide demand including GLP-1. https://samsungbiologics.com/media/company-news/samsung-biologics-announces-all-cash-offer-to-acquire-polypeptide
- Samsung Biologics Press Release “Samsung Biologics publishesamus for PolyPeptide public tender offer” (August 31, 2026). Samsung Peptide AG, the minimum entry ratio, expected completion, and 6 GMP factories in PolyPeptide. https://samsungbiologics.com/media/company-news/samsung-biologics-publishes-prospectus-for-polypeptide-public-tender-offer
- Samsung Biologics Press Release “Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion” (August 28, 2026). 1,385,000L in 2032 with the 6th to 8th factory. https://samsungbiologics.com/media/company-news/samsung-biologics-3-trillion-won-rights-offering
- Samsung Biologics Bioconjugation ADC’s exclusive plant enclosed (under OEL 1 ng/m3), up to 500L reaction equipment, process and analysis items, and investor of Life Science Fund (Aimed Bio, BrickBio). https://samsungbiologics.com/services/bioconjugation
- Samsung Biologics Official website "Milestones". Completed CGMP preparation for ADC dedicated factory (February 2025), S-HiCon (October 2024), split (November 2025), Samsung 。oids (June 2025). https://samsungbiologics.com/about/milestones
- Samsung Epis Holdings Official website "Subsidiary (subsi introduction)" (Korean). The peptide-related element technology platform for Samsung Bioepis (biosimilar, ADC, AAV) and Episnex Lab. https://www.samsungepisholdings.com/about/about03.do
- Samsung Biologics Official website (the source of logo image). https://samsungbiologics.com/
14. Response table of claims and sources
| Content | ||
|---|---|---|
| Official name, established in 2011, head office location, listed market | Facts | Source 2 https://samsungbiologics.com/common/fileDownload.do?_fdFileName_=cd21696118cd4a7daa6973c02d40f795.pdf&_colunmName_=attCnt0&_downloadIdx_=391&_fdFileOriName_=%5BSamsung%20Biologics%5D%202025%20Business%20Report.pdf&_fdSubPath_=investors |
| amidation of Samsung Epis Holdings, as of November 1, 2025, and the purpose of splitting (resolving conflicts of interest) | Facts | Source 1・2 https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515001658 |
| No development completed, no license-in-out technical alliance, no government subsidies. | Facts | Source 1 https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515001658 |
| Sales and Operating Income (Consolidated), 5, | Facts | Source 2 https://samsungbiologics.com/common/fileDownload.do?_fdFileName_=cd21696118cd4a7daa6973c02d40f795.pdf&_colunmName_=attCnt0&_downloadIdx_=391&_fdFileOriName_=%5BSamsung%20Biologics%5D%202025%20Business%20Report.pdf&_fdSubPath_=investors |
| Research and development costs (1,416 billion, 1,674 billion won) vs. sales ratio, research and development of 609 people, regional sales composition, antibody drug sales 95.6% | Facts | Source 1 https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515001658 |
| ADC factory completed and GMP Ready (up to the end of the first quarter of 2025), ADC injection factory construction contract (524 billion won), ADC DP line by 2027 and mother line of prefilled syringe | Facts | Source 1 https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515001658 |
| Agreement withigaerna to expand the ADC facility as a policy of 2026, investor of Life Science Fund (Araris, Phrontline, etc.), and ADC development contract with RigaChem | Facts | Source 2 https://samsungbiologics.com/common/fileDownload.do?_fdFileName_=cd21696118cd4a7daa6973c02d40f795.pdf&_colunmName_=attCnt0&_downloadIdx_=391&_fdFileOriName_=%5BSamsung%20Biologics%5D%202025%20Business%20Report.pdf&_fdSubPath_=investors |
| Consolidated sales forecast for 2026 (+15 - 20%) | Facts | Source 3 https://samsungbiologics.com/common/fileDownload.do?_fdFileName_=61a7b9d576694f6c8a10151dfb7067f8.pdf&_colunmName_=attCnt0&_downloadIdx_=382&_fdFileOriName_=%5BSamsung-Biologics%5D-2025-Q4-Earnings-Release.pdf&_fdSubPath_=investors |
| First commercial engineering run at ADC dedicated factory, acquire Rockville ($3.53 billion) and partner with CEPI・Eli Lilly | Facts | Source 4 https://samsungbiologics.com/media/company-news/samsung-biologics-reports-first-quarter-2026-financial-results |
| Earnings and operating income for the first half of 2026, cumulative orders of USD 27.2 billion, the composition of the Life Science Fund, the third fund, and the maximum forecast. | Facts | Source 5 https://samsungbiologics.com/media/company-news/samsung-biologics-reports-second-quarter-2026-financial-results |
| Buying to PolyPeptide (44.31CHF per share, approx. 14.6 billion CHF), conditions, maximum shareholder commitment, GLP-1 demand, geographical expansion to the United States, Europe and India | Facts | Source 6 https://samsungbiologics.com/media/company-news/samsung-biologics-announces-all-cash-offer-to-acquire-polypeptide |
| Samsung Peptide AG, today's purchase period (September 15 - October 12), expected to be completed until the end of 2026, PolyPeptide's 6 GMP factory | Facts | Source 7 https://samsungbiologics.com/media/company-news/samsung-biologics-publishes-prospectus-for-polypeptide-public-tender-offer |
| Capital increase and use of about 3 trillion KRW, the ratio and schedule of the number of new shares and market capital, and 1,385,000L | Facts | Source 8 https://samsungbiologics.com/media/company-news/samsung-biologics-3-trillion-won-rights-offering |
| ADC dedicated factory (under OEL 1 ng/m3), equipment, process and analysis items up to 500L | Facts | Source 9 https://samsungbiologics.com/services/bioconjugation |
| Completed CGMP preparation for ADC dedicated factory (February 2025), S-HiCon (October 2024), Samsung )oids (June 2025) | Facts | Source10 https://samsungbiologics.com/about/milestones |
| Peptide-related platform for Samsung Bioepis (biosimilar, ADC, AAV) and Episonic Labs | Facts | Source11 https://www.samsungepisholdings.com/about/about03.do |
| Drug /DDS Classification (Pharmaceu /DDS Biotech/Contract Development) | The calculation of this paper | This article. Company name is an example of a company handled by this series. |
| Biopharmaceu Market Scale and Growth Rate | Undetermined / Future | It is not adopted in this article because it is not listed in the source 1 but can not check the source of the estimate https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515001658 |
| The status of PolyPeptide’s Acquisition and Status of Public Buying | Undetermined / Future | Purchase period as of September 26, 2026. This article does not estimate the results https://samsungbiologics.com/media/company-news/samsung-biologics-publishes-prospectus-for-polypeptide-public-tender-offer |
| ADC contract number, customer name, sales, ADC’s DP line and prefilled syringe capability, the amount and content of contract with RigaChem and Li Lilly | Undetermined / Future | Not specified in the source 1-10. Not mentioned in this article https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515001658 |
| Joint research with universities on ADC and peptides | Undetermined / Future | Not listed in Source 1 and 2. This article does not break even if it is not present https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260515001658 |
| ADC to aim for a consistent contract that connects antibody → binding → filling in the company | Interpretation of this paper from the process diagram of the ADC plant and injection plant | |
| Read that peptide acquisitions have a meaning to spread the location of the factory to the United States, Europe and India | Comment from CEO and interpretation of this article from PolyPeptide | |
| Read that ADC technology is not in-house and use the technology of the investor and the customer. | Interpre of this document from the purpose of the description and division of the license | |
| Reading splitting and peptide acquisitions as a single policy, reading that the drug discovery and contract manufacturing of peptides are being divided into groups | Interpre of this paper from the source 1, 6, and 11. Both functions are not officially explained | |
| Reasons for use in single use and stainless steel, description of solid phase materials | General technical explanation. There is no reason or method in the primary material of the company | |
| Risks on the rise of the ADC business and the integration of different manufacturing technologies | Interpre of this paper from the stage of business and the personality of acquisition |
Last Updated:September 26, 2026/Troy Technical
All the figures in this article are based on the business report submitted by Samsung Biologics to the Financial Supervisory Office, the company's English Business Report, Financial Results, Official Release Site, and Samsung Epis Holdings' official website. We do not use estimates and media-based numbers of survey companies. The "、ulation" section is an interpretation that the article reads from the primary information and is not an announcement of the company. This paper is based on the business content of the company and does not recommend the use or effect of certain drugs.